DREDGECAP
NASDAQ·Surgical & Medical Instruments & Apparatus
DXCM

DEXCOM INC

DEXCOM INC (ticker: DXCM) is an NASDAQ-listed surgical & medical instruments & apparatus company. Its most recent SEC filing was a 8-K dated 2026-05-15. DredgeCap's extraction of DXCM's SEC filings surfaces no active distress signals from the most recent annual filing. DXCM reported $1.19B in revenue and $199.50M for the period ending 2026-03-31, with operating cash flow of $525.60M. Cash and equivalents stood at $1.12B (up 23.6% year-over-year). Total assets of $6.63B exceed total liabilities of $3.68B. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.

DXCM Overview
10-QApril 30, 20264/30/26· Quarter Ended March 31, 2026· Q-End 3/31/26

DXCM10-Q Filing

Track for Alerts

Financial Highlights

Structured-data extract from the filer's SEC-tagged XBRL. Every value below is sourced from a labeled XBRL concept; hover any cell to see the exact source. No AI summarization, no paraphrasing.

Income Statement

ItemMar 31, 2026Mar 31, 2025YoY
Revenue$1.19B$1.04B↑ +15.0%
Cost of Revenue$441.60M$447.00M
Operating Income (Loss)$255.30M$133.70M↑ +90.9%
Net Loss from Continuing Operations(derived)$199.50M$105.40M↑ +89.3%
Net Income (Loss) — Total$199.50M$105.40M↑ +89.3%

Balance Sheet

ItemMar 31, 2026Mar 31, 2025YoY
Total Assets$6.63B$6.75B
Total Liabilities$3.68B$4.49B
Stockholders' Equity$2.96B$2.27B↑ +30.5%
Accumulated Deficit$2.63B$1.70B
Cash and Cash Equivalents$1.12B$904.90M↑ +23.6%
Shares Outstanding385.90M392.10M

Cash Flow

ItemMar 31, 2026Mar 31, 2025YoY
Operating Cash Flow$525.60M$183.80M↑ +186.0%
Source filings — every value above is extracted verbatim from these SEC submissions:
Current DredgeCap Risk Profile
3.2/10
MODERATE RISK
Dilution Risk
LOW2.5/10
Liquidity Risk
LOW2.0/10
Debt Toxicity
MODERATE3.5/10
Profitability Risk
LOW2.8/10
Going Concern✓ Not flagged
The risk profile above reflects the latest cached DredgeCap analysis for DXCM. For the full filing-by-filing analyst report (red flags, primary risk driver, what moves the stock), open DXCM's company page.

What is a 10-Q?

A quarterly report covering the three months just ended. Includes unaudited condensed financial statements (balance sheet, income statement, cash flow), Management Discussion and Analysis (MD&A), and disclosure of material changes since the last annual report. Required for the first three fiscal quarters; the fourth quarter is rolled into the 10-K.

More on DXCM

Dilution Analysis
Debt Structure
Going Concern
Full Financials
Form-type explainers and 8-K item descriptions are derived from SEC documentation. Financial values are extracted from SEC-tagged XBRL — see the "Source filings" list above each table for direct EDGAR links to every cited filing. This page does not constitute investment advice. Always consult the original filing on SEC EDGAR for authoritative content, and consult a licensed financial advisor for investment decisions.